Drugs / EG12014
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03180242 | Mar → Aug 2016 | — | EirGenix, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03433313 | Oct 2018 → Jan 2022 | breast cancer | EirGenix, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG12014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03433313 ↗ |
| Route | Intravenous | “single-dose IV infusion over 90 min at 6 mg/kg” NCT03180242 ↗ |